1. Anonymous (2011) Guidance for industry and FDA staff—class II special controls guidance document: repetitive transcranial magnetic stimulation (rTMS) systems. US Food and Drug Administration Document number 1728. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm265269.htm
2. Anonymous (2015) General wellness: policy for low risk devices—guidance for industry and Food and Drug Administration staff. U.S. Food and Drug Administration Document number 1300013: http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm429674.pdf
3. Anonymous (2016) Information for patients. International Society for Magnetic Resonance in Medicine. http://www.ismrm.org/resources/information-for-patients/
4. Asashima M, Shimada K, Pfeiffer CJ (1991) Magnetic shielding induces early developmental abnormalities in the newt, Cynops pyrrhogaster. Bioelectromagnetics 12:215–224
5. Baek S, Choi H, Park H, Cho B, Kim S, Kim J (2019) Effects of a hypomagnetic field on DNA methylation during the differentiation of embryonic stem cells. Sci Rep 9(1):1333. https://doi.org/10.1038/s41598-018-37372-2